News | June 18, 2026
Moderna reshapes leadership and ops model as it pushes into oncology, rare disease
CEO Stéphane Bancel framed the changes as essential to scaling the business
CEO Stéphane Bancel framed the changes as essential to scaling the business
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
The collaboration aims to develop differentiated biologics that offer greater convenience and accessibility for patients
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
Approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device
The therapy also delivered significant improvements in key liver enzyme markers
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
